Mexico Becomes the First Market Worldwide to Receive Approval for Galderma’s Restylane® Shaype™ for Both Chin and Its First Jawline Indication
Galderma Group AG Registered Shares GALD
News
Galderma Finance Chief to Step Down, Months After Joining Company
Galderma Announces Proposed Board Appointments and Chief Financial Officer Transition
Galderma launches ALASTIN Restorative Eye Complex with TriHex+™, bringing new science-backed innovation to the entire eye area
Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines
Galderma Delivers Net Sales of 4.765 B USD in the First Nine Months, Up 25.1% at Constant Currency Year-on-Year, and Raises Full-Year Net Sales Guidance
AMWC Dubai 2026: Galderma Reinforces Its Injectable Aesthetics Leadership
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis
Skincare Specialist Galderma to Buy ZO Skin Health for $1.5 Billion — Update
Galderma to Buy ZO Skin Health for $1.5 Billion
Galderma Signs Agreement to Acquire ZO Skin Health, Strengthening Its Physician-Dispensed Skincare Offering
New Galderma Research Reveals More Than Half of Women Mistake Menopause-Related Skin Changes for Signs of Ageing
Fall Clinical 2026: Galderma Presents New Three-Year Nemluvio® Data Showing Deep and Lasting Skin Lesion and Itch Responses in Patients With Atopic Dermatitis Aged 12 and Older
30 Years of Restylane®: Reshaping the Aesthetics Field Through Science-Led, Patient-Centric Innovation
EADV 2026: Galderma’s New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis
EADV 2026: Galderma to Unveil New Data Advancing Understanding of Skin Diseases, Skin Longevity, and Real-world Patient Experiences
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies
Galderma’s Restylane® Volyme™ Demonstrates High Effectiveness, Satisfaction and a Robust Safety Profile in Chinese Patients With Temple Hollowing
Plastic surgery is booming with boomers. Here's how to cash in on the antiaging craze.
/C O R R E C T I O N — Cetaphil/
United States